Company Jaguar Health Inc Nasdaq

Equities

US47008L1061

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Bio Therapeutic Drugs

Inactive Instrument

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

USD in Million	2022	Weight	2023	Weight	Delta
Human Health 98.2 %	12	98.2 %	10	98.2 %	-18.34%
Animal Health 1.8 %	0	1.8 %	0	1.8 %	-19.53%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	12	100.0 %	10	100.0 %	-18.36%

Managers	Title	Age	Since
Lisa Conte FOU	Founder	65	06/13/06
Carol Lizak DFI	Director of Finance/CFO	60	01/19/01
Pravin Ramsewak Chaturvedi CTO	Chief Tech/Sci/R&D Officer	60	01/17/01
Jonathan Wolin CMP	Compliance Officer	62	01/18/01
Darlene P. Horton CTO	Chief Tech/Sci/R&D Officer	62	01/21/01
Peter C. Hodge IRC	Investor Relations Contact	-	-
Karen Brunke PRN	Corporate Officer/Principal	72	09/21/09
Ian Wendt PRN	Corporate Officer/Principal	-	-
David Sesin PRN	Corporate Officer/Principal	-	-
Steven King PRN	Corporate Officer/Principal	66	01/04/01

Members of the board	Title	Age	Since
Lisa Conte FOU	Founder	65	06/13/06
James Bochnowski CHM	Chairman	80	01/14/01
John Micek BRD	Director/Board Member	71	01/16/01
Jonathan Siegel BRD	Director/Board Member	50	29/18/29
Anula Kusum Jayasuriya BRD	Director/Board Member	67	01/22/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	9	0	0	92.16 %
Stock B	1	276,216,260	254,562,311 ( 92.16 %)	0

Name	Equities	%	Valuation
Fife Trading, Inc. 1.765 %	4,875,000	1.765 %	828 750 $
BlackRock Institutional Trust Co. NA 0.9398 %	2,595,782	0.9398 %	441 283 $
Uptown Capital LLC 0.6910 %	1,908,651	0.6910 %	324 471 $
Fredrick Waid 0.6841 %	1,889,565	0.6841 %	321 226 $
Commonwealth Equity Services LLC 0.3255 %	899,170	0.3255 %	152 859 $
Lisa Conte 0.1405 %	388,205	0.1405 %	65 995 $
Pravin Ramsewak Chaturvedi 0.0744 %	205,462	0.0744 %	34 929 $
Jonathan Wolin 0.0716 %	197,769	0.0716 %	33 621 $
Citadel Securities GP LLC 0.0700 %	193,330	0.0700 %	32 866 $
Vanguard Group, Inc. (Subfiler) 0.0696 %	192,335	0.0696 %	32 697 $

Jaguar Health, Inc.

200 Pine Street Suite 400

94104, San Francisco

http://www.jaguar.health

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs